Korean Journal of Transplantation (대한이식학회지)

The Korean Society For Transplantation (대한이식학회)
권호 표지
DOI QR코드

DOI QR Code

ABO Incompatible Living Donor Liver Transplantation: A Single Center Experience

  • Lee, Seung Hoon (Department of Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Choi, Ho Joong (Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • You, Young Kyoung (Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Dong Goo (Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Na, Gun Hyung (Department of Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2018.07.08
  • Accepted : 2018.10.26
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Background: This study examined the outcomes of ABO incompatible living donor liver transplantation (LDLT). The changes in the immunologic factors that might help predict the long term outcomes were also studied. Methods: Twenty-three patients, who underwent ABO incompatible LDLT from 2010 to 2015, were reviewed retrospectively. The protocol was the same as for ABO compatible LDLT except for the administration of rituximab and plasma exchange. The clinical outcomes and immunologic factors, such as isoagglutinin titer and cluster of differentiation 20+ (CD20+) lymphocyte levels were reviewed. Results: The center showed a 3-year survival of 64% with no case of antibody-mediated rejection. When transplantation-unrelated mortalities (for example, traffic accidents and myocardial infarction) were removed from statistical analysis, the 3-year survival was 77.8%. Although isoagglutinin titers continued to remain at low levels, the CD20+ lymphocyte levels recovered to the pre-Rituximab levels at postoperative one year. Conclusions: As donor shortages continue, ABO incompatible liver transplantation is a feasible method to expand the donor pool. On the other hand, caution is still needed until more long-term outcomes are reported. Because CD20+ lymphocytes are recovered with time, more immunologic studies will be needed in the future.

Keywords

References

  1. Starzl TE, Koep LJ, Halgrimson CG, Hood J, Schroter GP, Porter KA, et al. Fifteen years of clinical liver transplantation. Gastroenterology 1979;77:375-88. https://doi.org/10.1016/0016-5085(79)90294-4
  2. Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990;336:519-23. https://doi.org/10.1016/0140-6736(90)92082-S
  3. Rego J, Prevost F, Rumeau JL, Modesto A, Fourtanier G, Durand D, et al. Hyperacute rejection after ABO-incompatible orthotopic liver transplantation. Transplant Proc 1987;19:4589-90.
  4. Monteiro I, McLoughlin LM, Fisher A, de la Torre AN, Koneru B. Rituximab with plasmapheresis and splenectomy in abo-incompatible liver transplantation. Transplantation 2003;76:1648-9. https://doi.org/10.1097/01.TP.0000082723.02477.87
  5. Stewart ZA, Locke JE, Montgomery RA, Singer AL, Cameron AM, Segev DL. ABO-incompatible deceased donor liver transplantation in the United States: a national registry analysis. Liver Transpl 2009;15:883-93. https://doi.org/10.1002/lt.21723
  6. Kim JD, Choi DL, Kim SG, Lee AJ. Single-center experience of ABO-incompatible living-donor liver transplantation with a new simplified intravenous immunoglobulin protocol: a propensity score-matching analysis. Transplant Proc 2016;48:1134-8. https://doi.org/10.1016/j.transproceed.2016.02.040
  7. Kim SJ, Na GH, Choi HJ, Yoo YK, Kim DG. Surgical outcome of right liver donors in living donor liver transplantation: single-center experience with 500 cases. J Gastrointest Surg 2012;16:1160-70. https://doi.org/10.1007/s11605-012-1865-y
  8. Na GH, Kim DG, Choi HJ, Han JH, Hong TH, You YK. Interventional treatment of a biliary stricture after adult right-lobe living-donor liver transplantation with duct-to-duct anastomosis. HPB (Oxford) 2014;16:312-9. https://doi.org/10.1111/hpb.12151
  9. Demetris AJ, Jaffe R, Tzakis A, Ramsey G, Todo S, Belle S, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988;132:489-502.
  10. Uchiyama H, Mano Y, Taketomi A, Soejima Y, Yoshizumi T, Ikegami T, et al. Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange. Transplantation 2011;92:1134-9. https://doi.org/10.1097/TP.0b013e318231e9f8
  11. Usuda M, Fujimori K, Koyamada N, Fukumori T, Sekiguchi S, Kawagishi N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005;79:12-6. https://doi.org/10.1097/01.TP.0000149337.40911.E4
  12. Song GW, Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transplant 2016;16:157-70. https://doi.org/10.1111/ajt.13444
  13. Lee J, Lee JG, Lee JJ, Kim MS, Ju MK, Choi GH, et al. Results of ABO-incompatible liver transplantation using a simplified protocol at a single institution. Transplant Proc 2015;47:723-6. https://doi.org/10.1016/j.transproceed.2015.02.004
  14. Lee SD, Kim SH, Kong SY, Kim YK, Park SJ. Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. Transpl Immunol 2015;32:29-34. https://doi.org/10.1016/j.trim.2014.11.216
  15. Kim JM, Kwon CH, Joh JW, Kang ES, Park JB, Lee JH, et al. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor. J Hepatol 2013;59:1215-22. https://doi.org/10.1016/j.jhep.2013.07.035
  16. Lee EC, Kim SH, Shim JR, Park SJ. A comparison of desensitization methods: rituximab with/without plasmapheresis in ABO-incompatible living donor liver transplantation. Hepatobiliary Pancreat Dis Int 2018;17:119-25. https://doi.org/10.1016/j.hbpd.2018.02.005
  17. Raut V, Mori A, Kaido T, Ogura Y, Taku I, Nagai K, et al. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 2012;93:99-105. https://doi.org/10.1097/TP.0b013e318239e8e4
  18. Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Harada N, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. Transplantation 2009;88:303-7. https://doi.org/10.1097/TP.0b013e3181adcae6

Cited by

  1. Desensitization in HLA Incompatible Transplantation vol.30, pp.1, 2018, https://doi.org/10.17945/kjbt.2019.30.1.1